Raphael Pharmaceutical Inc.
Close on Oct 16, 2026
- Market cap
- $30.47M
- P/E (TTM)
- 75.5
- Dividend yield
- –
About Raphael Pharmaceutical
Medicinal Chemicals & Botanical Products, SIC 2833
Raphael Pharmaceutical Inc. is a clinical-stage pharmaceutical drug research and development company focused on discovering and developing therapies derived from cannabinoids, specifically low-THC cannabidiol (CBD) formulations. The company focuses on developing treatment candidates for inflammatory and autoimmune conditions, including rheumatoid arthritis, asthma, and COVID-19-related hyperinflammatory syndrome. Its product pipeline features a lead formulation for rheumatoid arthritis, an asthma candidate in pre-clinical development, and a clinically tested dietary supplement marketed under the RaphaWell brand for rheumatoid arthritis support. As an early-stage research entity, its customer base centers on prospective healthcare markets, commercial distributors, and potential pharmaceutical licensing partners.
The company operates without internal manufacturing facilities, collaborating with third-party research entities such as Rambam Med-Tech Ltd. in Israel and clinical research managers in Santa Monica, California, to conduct laboratory studies and clinical trials. Raphael Pharmaceutical Inc. maintains its principal executive offices in Tel Aviv-Jaffa, Israel.
Summary of the business section of Raphael Pharmaceutical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Raphael Pharmaceutical Inc.
- Founded
- 2007
- Headquarters
- Las Vegas, NV
- Address
- Suite 105 - 5348 Vegas Dr. 89108
- Phone
- (702) 442-1166
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Elkana Amitai CPA, Mitzpe Netofa, Israel
Stock & identifiers
- Ticker
- RAPH
- Exchange
- OTC
- Shares outstanding
- 20M, Aug 14, 2026
- Public float
- $9.43M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1415397
- EIN
- 26-0204284
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Shlomo Pilo | Chief Executive Officer, Director | 7,767,402 |
| Hayon Igal Louria | Chief Technology Officer | 1,349,000 |
| Zvi Laufer Laor | Director | – |
| Yehuda Eliya | Director | 352,000 |
| Ajay Kumar Dhadha | Director | 754,820 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 11, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 7, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 15, 2021 | Late filing | Notification of late filing |
| May 14, 2021 | Name change | Name changed from Easy Energy Inc to Raphael Pharmaceutical Inc. |
| May 29, 2013 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 1, 2010 | Late filing | Notification of late filing |
| Jan 20, 2010 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 16, 2009 | Late filing | Notification of late filing |
| Sep 10, 2009 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 6, 2009 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 14, 2008 | Late filing | Notification of late filing |
| Aug 14, 2008 | Late filing | Notification of late filing |